Fig 1: rhIL-22BP-ABD decreases the expression of pro-inflammatory cytokines and STAT3 signaling pathway in psoriatic mice. A The representative images of the H&E-stained skin sections of different treatment groups. B Expression of IL-6 in different treatment groups by ELISA (n = 5). C Expression of TNF-α in different treatment groups by ELISA (n = 5). D The expressions of IL-22, IFN-γ, IL-1β and p-STAT3 proteins in different treatment groups were detected by Western blot. Quantitative data are presented as mean ± standard deviation (n = 5). Statistical significance is indicated as follows: ****P < 0.0001, and ns means no significant difference
Fig 2: The identification of rhIL-22BP-ABD. A rhIL-22BP-ABD was performed on immunoblotting with anti-His-tag antibody by Western blot. B Determination of rhIL-22BP-ABD peptide map by mass spectrometry. C The effect of 5, 10 and 50 ng/mL IL-22 on the proliferation of HaCaT cells was detected by CCK8 assay. D The 50 μg/mL rhIL-22BP-ABD inhibits in vitro HaCaT cell proliferation stimulated by 10 ng/mL IL-22. E The inhibitory effect of 10, 50 and 100 μg/mL rhIL-22BP-ABD on HaCaT cell proliferation stimulated by 10 ng/ml IL-22. Quantitative data are presented as mean ± standard deviation (n = 4). Statistical significance is indicated as follows:*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ns means no significant difference
Supplier Page from MedChemExpress for IL-22 Protein, Human